R&D in drug design
and profiling
Grounded in the fields of medicinal chemistry and life sciences, Molecular Research Pharma CT is a contract research organization that stems from decades of R&D in drug design and profiling.
It is mostly specialized in rational drug design and synthesis but has the know-how and capabilities to deal with life-sciences research.
ABOUT US
Molecular Research Pharma CT is a CRO (Contract Research Organization) company for the research and development of new molecules derived from research in the areas of pharmaceuticals, nutraceuticals, food, and dietary supplements, pharmaceuticals and pharmaceutical analytical chemistry
The CRO offers, therefore, a service for present and future projects relatively:
-Development of new molecules;
-Ligand- and -Structure Based Drug Design;
-Repurposing and repositioning of existing molecules;
-Computational Chemistry/Biochemistry comprehensive of Molecular Dynamics;
-Nutraceuticals and/or food supplements.
-Analytical methods .
Moreover, it boasts a vast network of collaborations including an international partnership for the development of new ligands to be applied in the field of diabetes, Alzheimer Disease (AD) and cancer.
TARGET MARKET: The company, through its technologies targets the following markets:
- The drug-repositioning market: this market shows a TAM of 24.4b USD and projects a CAGR of 5.1% on average until 2023.
SERVICES
Molecular Research Pharma CT carries out the activities of a pharmaceutical research laboratory, with an application in the field of bioscience, biotechnology, and pharmacology, acting as a support to all companies in the portfolio of Cube Labs.
The spin-off offers support services in the development of molecules in the preclinical phase to pharmaceutical and biotech companies. Specifically, starting from the discovery and selection of new molecules, MRC deals with the non-clinical studies of pharmacology and toxicology, as well as the production of product quality data.
The procedures implemented are in accordance with GLP (Good Laboratory Practices).
The goal is to simplify the process of developing and marketing new drugs, so those new safe products can reach patients faster.
To accomplish this mission, Molecular Research Pharma CT relies on the expertise of its team and highly innovative equipment. The MRC project was born with the aim of carrying out research and development of new molecules in the therapeutic field, comprehensive of drugs active against rare diseases.